Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY86-6150 in Hemophilia A or B with Inhibitors
NCT01625390Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2012
- Primary completion
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, open-label trial of dalcinonacog alfa in hemophilia A and hemophilia B (HB) (3 arms), sponsored by Bayer. Primary endpoints: Successful treatments of bleeding episodes and Proportion of successful treatments of bleeding episodes on subject level. Started Jun 2012; status: completed.
02
Drugs
dalcinonacog alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT01625390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625390.